David Andersen has represented a variety of companies, individuals, private equity funds and institutional clients in general corporate and securities matters, with an emphasis on the representation of emerging-growth high-technology and biotechnology companies. In this capacity, Mr. Andersen has assisted clients in structuring, developing and positioning numerous business enterprises for venture capital and private equity investment, growth through acquisitions and eventual sale or initial public offerings.
Mr. Andersen’s practice includes counseling clients in connection with all phases of the corporate life cycle, including issues related to initial formation and capitalization, public and private offerings of debt and equity securities, mergers and acquisitions, strategic alliances and joint ventures, and recapitalizations and corporate restructurings. Mr. Andersen regularly assists companies with the purchase and sale of stock or assets, mergers and other change of control transactions. In addition, Mr. Andersen has represented a number of public companies in diverse industries (including technology, healthcare, and entertainment) in all aspects of securities reporting and compliance, and advises clients with respect to a wide range of corporate governance issues, equity incentive plans and related matters.